Several retrospective cohort studies have explored the association between the use of GLP-1RAs and the risk of intestinal obstruction compared to SGLT2 inhibitors in T2DM patients, with mixed outcomes. The gene discussed is SLC5A2; the disease is intestinal obstruction.